Abstract. Aberrant gene methylation is frequently observed in various cancers and plays an important role in carcinogenesis, cancer progression and drug responsiveness. The aim of this study is to identify colorectal cancer specific gene methylation determining chemosensitivity to S-1/CPT-11 therapy. The gene methylation of CHFR, p16, RUNX3, Ecadherin, MGMT, hMLH1, ABCG2, UGT1A1 and BNIP3 genes were analyzed in 27 colorectal cancer tissues by quantitative methylation-specific PCR (q-MSP). All 27 patients were postoperatively treated by S-1/CPT-11 therapy targeting the metastatic lesion and the recurrent tumor. Thereafter, the patients were divided into a responder group (RG) or a non-responder group (NRG) according to the effect of the chemotherapy. There were 13 cases of RG (48.1%) and 14 cases of NRG (51.9%). The methylation level in CHFR, RUNX3 and BNIP3 was significantly higher in cancer lesions in comparison to the non-cancerous lesion. Only methylation of the BNIP3 gene was significantly higher in primary cancer tissue of the NRG than the RG. The correlation between the BNIP3 methylation status and time to progression (TTP) suggested that the low methylation group (n=16) resulted in a significantly longer TTP, in comparison to the high methylation group (n=11; P=0.004). The methylation level of BNIP3 showed a significant inverse correlation with the mRNA expression suggesting the DNA methylation suppressed BNIP3 expression (r=-0.466, P=0.021). In conclusion, BNIP3 gene methylation is a possible marker predicting a poor response to the S-1/CPT-11 combined therapy in colorectal cancer.
Introduction
Colorectal cancer (CRC) is one of the most common malignancies and the third leading cause of cancer related deaths (1) . Surgical resection is the most powerful treatment for the complete cure of CRC patients. However, a surgical resection is occasionally impossible due to the advanced stage in several patients. Furthermore, a local or distant tumor recurrence may develop even if a curative resection of the primary tumor is performed. Therefore, effective chemotherapy is an important strategy for prolonging the survival of patients with CRC. Various drugs have been developed and administered to patients with advanced or recurrent CRC. However, an ineffective drug allows further growth of the tumor and results in an unfavorable outcome. If the drug efficacy is predicted before the treatment, the information will help to select the optimal anticancer drugs individually, and socalled tailor-made-therapy might improve the outcome of chemotherapy.
Several predictive factors for chemosensitivity have been investigated for several solid tumors. Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and ortate phosphoribosyltransferase (OPRT), which are critical enzymes in the metabolism of 5-fluorouracil (5-FU) could be important factors determining chemosensitivity to 5-FU or the modified agent, S-1 (2-4). Besides, aberrant promoter methylation of tumor suppressor genes, DNA repair genes, and cell cycle checkpoint genes are frequently found in human primary CRC and show a significant correlation with carcinogenesis, tumor progression and chemosensitivity (5) (6) (7) (8) (9) . There is a relationship between aberrant gene methylation and chemosensitivity to anticancer drugs, for example CHFR and microtubule inhibitors in gastric cancer tissues and cell lines, p16 and 5-FU-based therapy in gastric cancer tissues, hMLH1 and 5-FU-based therapy in colorectal cancer tissues (10) (11) (12) .
We recently reported that a phase I/II study of Tegafur, gimeracil, oteracil potassium (S-1) plus CPT-11 therapy in 33 metastatic CRC patients demonstrated a response rate of 58% (13) . The present study examined DNA methylation of 9 cancer related genes using primary CRC tissues from 27 patients. The nine genes include CHFR (checkpoint with forkhead and ring finger domains), p16 (cyclin-dependent kinase inhibitor 2A), RUNX3 (runt-related transcription factor 3), E-cadherin, MGMT (O 6 -methylguanin DNA methyltransferase), hMLH1 (mutL homolog 1), ABCG2 (ATPbinding cassette, sub-family G, member 2), UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) and BNIP3 (BCL2/adenovirus E1B 19 kDa interacting protein 3), which all show frequent methylation in several cancer types (8,10-12,14-17). Three genes expressing the CRC specific methylation were isolated through a quantitative methylationspecific PCR (q-MSP) method using 27 paired cancer tissues and the non-cancerous mucosa specimens. Subsequently, the gene methylation was examined in order to determine whether or not the methylation status correlates with the responsiveness to S-1/ CPT-11 therapy. The aim of this study was to identify CRC specific gene methylation determining the chemosensitivity to S-1/ CPT-11 therapy.
Materials and methods
Patients and tissue samples. Seventy-one CRC patients were treated by S-1/CPT-11 therapy from 2004 to 2008 at the Department of Surgery, Saga University Hospital. Twentyseven of the 71 patients underwent a surgical resection of the primary tumor. A metastatic lesion was concomitantly found during the surgery in 15 cases (55.6%), whereas a recurrent tumor developed postoperatively in 12 cases (44.4%). Informed consent was obtained from all the patients before the collection of the samples and the study protocol was approved by the Ethics Committee of Saga University, Faculty of Medicine. CRC tissues and non-cancerous tissues were obtained at surgery and stored at -80˚C until extraction of genomic DNA and RNA. The 27 patients included 10 (37.0%) females and 17 (63.0%) males. The mean age of the patients was 65.5 (ranging from 40 to 84 years). The maximal response to S-1/CPT-11 therapy was assessed on the metastatic lesion or the recurrent tumor according to by the response evaluation criteria in solid tumors (RECIST) (18) . Assessment of the response was based on the RECIST criteria, in which the Table I . Primer and probe sequence of LightCycler system for q-MSP. 
responder group (RG) included complete response (CR) and partial response (PR), while the non-responder group (NRG) indicated stable disease (SD) and progression disease (PD). The duration of S-1/CPT-11 effect was evaluated by the time to tumor progression (TTP; median: 11.0 months; range: 1.6-53.0 months). Fifteen of 27 (55.6%) patients were treated by S-1/CPT-11 therapy as the first treatment. The other 12 (44.4%) patients had been treated by other regimens and underwent S-1/CPT-11 therapy as 2nd-4th line therapy. The pretreatment regimens included tegafur-uracil/leucovorin (LV) therapy (7 cases), l-LV/5-FU therapy (5 cases), S-1 monotherapy (2 cases), tegafur-uracil monotherapy (1 case), and doxifluridine (5'-DFUR)/CPT-11 therapy (1 case). The treatment regimens and details were previously reported (13) .
DNA extraction and sodium bisulfite modification and quantitative methylation-specific PCR. The genomic DNA from the tissue samples was isolated using a DNA extraction kit (EZ1 DNA tissue kit, Qiagen, Hilden, Germany). Bisulfite modification was carried out using 2 μg of genomic DNA by MethylEasy™ Xceed (Human Genetic Signitures, North Ryde, Australia) according to the manufacturer's instructions. Modified DNA was suspended in 100 μl TE buffer. Twenty-seven primary CRC tissue specimens were analyzed for the methylation status of 10 genes (CHFR, p16, RUNX3, E-cadherin, MGMT, hMLH, ABCG2, UGT1A1, BNIP3 and ß-actin as an internal marker). For q-MSP, an aliquot of 2 μl was amplified by PCR using a primer set along with TaqMan probe specific to methylated sequences. A q-MSP (MethyLight) was carried out through LightCycler™ instrument system (Roche, Mannheim, Germany) using the LightCycler ® TaqMan ® Master (Roche) as previously described (19) . The primer sequences are shown in Table I (11, (20) (21) (22) (23) (24) . After a denaturing step at 95˚C for 10 min, PCR amplification was performed with 45 cycles of 15 sec denaturing at 95˚C, 5 sec annealing at 60˚C and a 10 sec extension at 72˚C. These experiments were carried out in triplicate and the mean value was then calculated. The methylation level of the target gene was normalized by ß-actin.
RNA extraction, conversion to cDNA and quantitative reverse transcriptase polymerase chain reaction (q-RT-PCR).
The total RNA from 27 paired of non-cancerous mucosa and the matched cancerous lesion (in 2 cases, mRNA was not high quality) was extracted using the Isogen (Nippon Gene, Toyama, Japan) according to the manufacturer's method. A 500-ng aliquot of RNA was converted into cDNA by reverse transcriptase using a ReverTra Ace ® q PCR RT kit (Toyobo, Osaka, Japan) according to the manufacturer's instruction. cDNA was suspended in 50 μl TE buffer. In order to quanti- ONCOLOGY REPORTS 23: 191-197, 2010 Table II. Primer and probe sequence of LightCycler system for q-RT-PCR.
Forward: CGCAGACACCACAAGATACC (this study) Reverse: GAATATTTTCCGGCCGACTT Probe: 5'-FAM-GGGTATCTGTTTCAGAAGCCC-3'BHQ
GAPDH
Forward: CGAGATCCCTCCAAAATCAA (this study) Reverse: TTCACACCCATGACGAACAT Probe: 5'-FAM-CGCTGAGTACGTCGTGGAGTCCACT-3' BHQ  ------------------------------------------------------------------------------------------------ ----- Table III . Clinicopathological characteristics of patients. 
tatively estimate the expression level of mRNA, polymerase chain reaction (PCR) amplification was performed on a Light-Cycler instrument system (Roche) using LightCycler TaqMan Master (Roche) according to the previously report (19) . The primer sequences are shown in Table II . After denaturing step at 95˚C for 10 min, PCR amplification was performed with 45 cycles of 15 sec denaturing at 95˚C, 5 sec annealing at 60˚C and a 10 sec extension at 72˚C. These experiments were carried out in triplicate and the mean value was then calculated. The mRNA expression of the target gene was normalized by GAPDH.
Data analysis and statistics. The statistical analysis was performed using the Mann-Whitney U test or Welch test with the Komlogorv-Sminov test. The cumulative TTP rate was computed according to the Kaplan-Meier method and compared between groups by the log-rank test. Spearman's correlation test was used to assess the correlation between the methylation level and mRNA expression. Statistical analyses were done with StatMate III (ATM Co., Ltd., Tokyo, Japan). A P-value <0.05 was considered statistically significant.
Results
The clinical characteristics of the 27 patients are summarized in Table III . The clinical stages of all patients were grouped as beyond Dukes B at the operation. There were 13 patients in the RG (48.1%) and 14 in the NRG (51.9%). Aberrant gene methylation. The methylation level for 9 genes, CHFR, p16, RUNX3, E-cadherin, MGMT, hMLH1, ABCG2, UGT1A1 and BNIP3 was initially assessed by q-MSP analysis using the 27 paired non-cancerous mucosa and primary cancer specimens (Fig. 1) . The methylation level of CHFR, RUNX3 and BNIP3 was significantly higher in the cancer lesions in comparison to the non-cancerous lesion (P=0.001, P=0.006, P=0.006). On the contrary, ABCG2 and UGT1A1 showed significantly higher methylation in non-cancerous mucosa than the cancer specimens (P=0.043, P=0.024). The methylation level of p16, E-cadherin, MGMT and hMLH1 showed no statistical differences between the non-cancerous and cancer specimens. Based on the results, CHFR, RUNX3, and BNIP3 were determined to carry the cancer specific gene methylation and subjected to further analysis. The methylation level of CHFR, RUNX3 and BNIP3 gene in the cancer specimens was compared between the RG and NRG (Fig. 2) .
As a result, the methylation level of only BNIP3 was significantly higher in the NRG than in the RG (P=0.031).
Correlation between BNIP3 gene methylation and time to progression. The BNIP3 methylation status and TTP were analyzed to assess the efficacy of S-1/CPT-11 therapy. Patients were divided into a high methylation (n=11) and low methylation group (n=16), which was determined according to an average of the methylation level in the cancerous lesion (mean, 0.1651; range, 0.0122-0.6037). The result indicated that the low methylation group showed a significantly longer term to TTP, in comparison to the high methylation group (P=0.004; Fig. 3 ).
BNIP3 expression in cancerous lesion. BNIP3 mRNA expression was quantitatively analyzed in cancer specimens from the 27 CRC patients. The BNIP3 mRNA level tended to be ONCOLOGY REPORTS 23: 191-197, 2010 Figure 2. Methylation level between the responder group (RG; left bar) and non-responder group (NRG; right bar). CHFR and RUNX3 did not demonstrate significant differences between the RG and NRG. Only BNIP3 showed a higher level in the NRG than the RG. Figure 3 . Time to progression curves stratified according to the results of the BNIP3 methylation level. The 27 patients were divided into low and high methylation groups (n=16, n=11) according to the average of the methylation level. A significant difference was observed between the low and high methylation group using the Kaplan-Meier method. Figure 4 . BNIP3 mRNA expression between the responders (left bar) and non-responders (right bar) in the primary cancer lesion. No statistical differences were observed between both lesions. However, the non-responder lesion tended to be lower than responder lesion.
lower in the NRG than in the RG, although there was no statistically significat difference (P=0.165; Fig. 4 ). In addition, the correlation between methylation and mRNA level was analyzed in the cancer lesions. The methylation level of BNIP3 showed a significant inverse correlation with the mRNA expression (r=-0.466, P=0.021; Fig. 5 ).
Discussion
Various treatment regimens have been examined in chemotherapy against CRC. A phase I/II study assessed the toxicity and efficacy of S-1/CPT-11 combined therapy for metastatic CRC (13, 25) . The result showed that a response to the S-1/CPT-11 combined therapy was obtained in 19 of 33 (58%) patients without any significant toxicity, suggesting the efficacy of S-1/CPT-11 against metastatic CRC (13). However, this combination therapy did not provide any therapeutic benefit to the remaining 14 of 33 (42%) patients. If a molecular marker could identify the responders before the treatment, targeting the responders could increase the response rate to 100%. Conversely, another regimen might be considered for the patients identified as non-responder to S-1/ CPT-11 treatment.
S-1, a biochemical modulator of 5-FU, is an oral DPD inhibitory fluoropyrimidine based on the biochemical modulation of 5-FU (26). S-1 was approved in Japan for gastric, colorectal, head and neck, breast, pancreas, biliary tract and lung cancer. On the other hand, CPT-11 is a derivative of camptothecin and a potent DNA topoisomerase I (topo-I) inhibitor that forms stable topo-I DNA-cleavable complexes and inhibits the progression of the replication fork (27) . CPT-11 has no cross-resistance with 5-fluorouracil (5-FU) and functions through a novel molecular mechanism (28) .
This study analyzed promoter hypermethylation of the cancer related genes in 27 paired non-cancerous mucosa and primary cancers. Nine of the cancer related genes, CHFR, p16, RUNX3, E-cadherin, MGMT, hMLH1, ABCG2, UGT1A1 and BNIP3, were chosen for methylation analysis, because frequent gene methylation has been reported in solid cancers, including CRC (5) (6) (7) (8) (10) (11) (12) (13) (14) (15) (16) (17) (20) (21) (22) (23) (24) . A significant correlation between gene methylation or expression and chemosensitivity to 5-FU, S-1 and CPT-11 has been reported for p16 (11) , MGMT (29) , hMLH1 (12), ABCG2 (16, 30) , UGT1A1 (14) and BNIP3 (31) .
Aberrant gene methylation is frequently observed in the CpG rich region in the promoter of various cancer related genes in various solid tumors. Gene methylation in cancer cells leads to epigenetic gene silencing and plays an important role in carcinogenesis, cancer progression and drug resistance (5) (6) (7) (8) (9) . A methylation analysis in cancer tissues has been widely examined by the MSP method. However, the conventional procedure is not able to assess the methylation level in the cancer tissues.
The present study evaluated the methylation levels of 9 cancer related genes by q-MSP method in non-cancerous mucosa as well as cancer lesion. The results demonstrated the methylation level of CHFR, RUNX3 and BNIP3 genes was significantly higher in cancer tissue than in non-cancerous mucosa (Fig. 1) . However, p16, E-cadherin MGMT, hMLH1, ABCG2 and UGT1A1 did not show increased methylation in cancer specimens from the 27 patients (Fig. 1) . CHFR, RUNX3 and BNIP3, which express CRC specific methylation, were subsequently investigated to determine the correlation with chemosensitivity to S-1/CPT-11 therapy. The BNIP3 methylation level was significantly higher in the non-responders than the responders (Fig. 2) . TTP, which represents the efficacy duration of this therapy, was significantly longer in the low methylation group, in comparison to the high methylation. Taken together, these results suggested that BNIP3 gene methylation in the CRC cells decreased the responsiveness to S-1/CPT-11 therapy.
Solid tumors often contain a hypoxic region, which is associated with the resistance to chemotherapy and radiation (32) . BNIP3 was originally identified as a protein that interacts with adenovirus E1B 19-kDa protein (33) . The BNIP3 expression is known to be up-regulated by hypoxia, while also inducing apoptosis in cancer cells (34) . However, BNIP3 expression is frequently silenced by DNA methylation and histone deacetylation in CRC (8, 35) . Abe et al (36) reported that demethylation, using a methyltransferase inhibitor, restores the expression of BNIP3 and induces hypoxiamediated cell death in pancreatic cancer. Erkan et al (31) reported that the down-regulation of BNIP3 resulted in increased resistance to 5-FU and gemcitabine. The authors demonstrated that the loss of BNIP3 expression occurs late in pancreatic cancer and contributes to resistance to chemotherapy, resulting in the worsened prognosis. These results suggested that the aberrant BNIP3 methylation in cancer cells, which suppresses expression, allows the tumors to escape apoptosis in response to hypoxia and chemotherapy. The present study demonstrated the decreased expression of BNIP3 in the NRG in comparison to the RG (Fig. 4) . Moreover, the methylation level of BNIP3 was inversely correlated with the mRNA level in the 27 cancer lesions (Fig. 5) . These results suggest that the epigenetic gene silencing of BNIP3 by DNA methylation occurs in the CRC tissues and causes the chemoresistance to S-1/CPT-11 treatment. Figure 5 . Analysis of the correlation between the levels of BNIP methylation and mRNA expression in primary cancer lesions. Spearman's correlation analysis showed that methylation level was significantly correlated with the mRNA expression.
In conclusion, BNIP3 gene methylation is a possible marker predicting a poor response to S-1/CPT-11 combined therapy in colorectal cancer. Although it is necessary to increase the number of patients analyzed, tailor-made therapy according to the BNIP3 gene methylation might potentially improve the efficacy of S-1/CPT-11 therapy against CRC.
